Axplora has announced a multi-million-euro investment to expand lyophilisation capacity at its Le Mans facility, alongside the appointment of François Houbart as Head of Site, as demand for antibody-drug conjugate (ADC) manufacturing continues to rise.
The contract development and manufacturing organisation (CDMO) said the investment will strengthen freeze-drying capabilities at its French site, enabling faster, more predictable ADC development and supply for biotech and pharmaceutical customers.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.